Floods, landscape modifications and population dynamics in anthropogenic coastal lowlands: the Polesine (northern Italy) case study

It is widely recognized that the complex relationship between humans, soil, and water has become increasingly complicated due to anthropogenic activities, and is further expected to worsen in the future as a result of population dynamics and climate change. The present study aims at shedding light on the multifaceted links between floods, landscape modifications, and population dynamics in anthropogenic coastal lowlands, using a large flood-prone area (the Polesine Region, northeastern Italy) as a significant case study. Based on the analysis of historical events and the results of hydraulic modeling, it is shown that human interventions on both the landscape and the subsoil have substantially altered the flooding dynamics, exacerbating hydraulic hazard. Furthermore, the combined analysis of people and assets exposure to inundation reveals that flood risk is not properly taken into account in land-use planning, nor it is properly understood by people living in areas subject to low-probability, high-impact flooding events

Sistema integrato di previsione delle piene in tempo reale nel bacino idrografico Brenta-Bacchiglione

-Modello idrologico-idrodinamico per la previsione delle piene in tempo reale nel Brenta-Bacchiglione. -Interfaccia grafica GIS funzionale alla gestione delle emergenze in corso di evento. -Limitazione dell\u2019incertezza delle condizioni iniziali forzando il modello con misure di precipitazione e di livello. -Buona precisione e affidabilit\ue0 del sistema confermate dalle simulazioni di eventi passati

The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic

Specific immune suppression types have been associated with a greater risk of severe COVID-19 disease and death. We analyzed data from patients >17 years that were hospitalized for COVID-19 at the “Fondazione IRCCS Ca′ Granda Ospedale Maggiore Policlinico” in Milan (Lombardy, Northern Italy). The study included 1727 SARS-CoV-2-positive patients (1,131 males, median age of 65 years) hospitalized between February 2020 and November 2022. Of these, 321 (18.6%, CI: 16.8–20.4%) had at least one condition defining immune suppression. Immune suppressed subjects were more likely to have other co-morbidities (80.4% vs. 69.8%, p < 0.001) and be vaccinated (37% vs. 12.7%, p < 0.001). We evaluated the contribution of immune suppression to hospitalization during the various stages of the epidemic and investigated whether immune suppression contributed to severe outcomes and death, also considering the vaccination status of the patients. The proportion of immune suppressed patients among all hospitalizations (initially stable at <20%) started to increase around December 2021, and remained high (30–50%). This change coincided with an increase in the proportions of older patients and patients with co-morbidities and with a decrease in the proportion of patients with severe outcomes. Vaccinated patients showed a lower proportion of severe outcomes; among non-vaccinated patients, severe outcomes were more common in immune suppressed individuals. Immune suppression was a significant predictor of severe outcomes, after adjusting for age, sex, co-morbidities, period of hospitalization, and vaccination status (OR: 1.64; 95% CI: 1.23–2.19), while vaccination was a protective factor (OR: 0.31; 95% IC: 0.20–0.47). However, after November 2021, differences in disease outcomes between vaccinated and non-vaccinated groups (for both immune suppressed and immune competent subjects) disappeared. Since December 2021, the spread of the less virulent Omicron variant and an overall higher level of induced and/or natural immunity likely contributed to the observed shift in hospitalized patient characteristics. Nonetheless, vaccination against SARS-CoV-2, likely in combination with naturally acquired immunity, effectively reduced severe outcomes in both immune competent (73.9% vs. 48.2%, p < 0.001) and immune suppressed (66.4% vs. 35.2%, p < 0.001) patients, confirming previous observations about the value of the vaccine in preventing serious disease

Impact of design conditions on energy use: the case study of a health care facility

Heating, ventilation and air conditioning (HVAC) systems in healthcare facilities provide a broad range of services; in particular, ventilation is used extensively to provide safe and comfortable environments for patients and medical staff, affecting the distribution pattern of airborne particles. Primary patient treatment areas such as surgical departments are supplied by specific emitters that undergo continuous maintenance and inspection. Improperly operating and maintained HVAC systems can even become a source of microorganisms. Due to 24 hours/day, 7 days/week operation, healthcare facilities are responsible of large quantities of energy consumption. This works aims to assess the energy consumption of a surgical unit designed in compliance with ASHRAE 170, UNI 11425 and HTM 03-01, which led to different design approaches for the definition of ventilation rates, showing the impact of heterogeneous guidelines on the energy use; the standards defined design criteria implemented in an energy model carried out with the dynamic tool TRNSYS, performing in three different climatic conditions. Results show that energy demand varies significantly depending on the standard used, highlighting the importance of a unique reference standard describing technical recommendations for HVAC systems design in operating/surgical rooms to obtain safe and clean environments while avoiding energy waste

In vitro Assessment of Solar Filters for Erythropoietic Protoporphyria in the Action Spectrum of Protoporphyrin IX

Introduction: Subjects with erythropoietic protoporphyria rely on broad-spectrum sunscreens with high sun protection factor, which is not informative on efficacy in the absorption spectrum of protoporphyrin IX, spanning visible radiation and peaking around 408 nm. Photoactivation of protoporphyrin IX is responsible for painful skin photosensitivity in erythropoietic protoporphyria. The authors assessed the protective efficacy of six sunscreens in vitro in the absorption spectrum of protoporphyrin IX. Method: Transmittance measurements were performed in the 300-850 nm wavelengths on samples of six photoprotective products applied to polymethyl methacrylate plates. Porphyrin protection factor was calculated in the 300-700 nm region to provide a measurement for the efficacy of each product based on the action spectrum of protoporphyrin IX. Results: Product A showed the highest porphyrin protection factor among tested products with a median value of 4.22. Product A is a sunscreen containing organic filters, titanium dioxide and synthetic iron oxides, pigmentary grade active ingredients that absorb visible radiation. Other products showed inefficient protection in the visible, with transmittance between 75 and 95% at 500 nm. The low porphyrin protection factor of inorganic filter product B was attributed to particle micronization, as declared by the manufacturer. Conclusion: Adding porphyrin protection factor to sunscreen labeling could help patients with erythropoietic protoporphyria and other photosensitivity disorders identify products tailored on their specific needs. The development of sunscreens providing protection from visible radiation and excellent cosmetical tolerability could improve the lifestyle of patients with erythropoietic protoporphyria

Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies

Background: Immunological treatments (immune checkpoint inhibitors [ICIs], chimeric antigen receptor T [CAR-T] cells, bispecific T-cell engagers [BiTEs]) have deeply changed the treatment of several cancers. However, the impact of these treatments on the risk of developing infections has not been completely ascertained yet. Methods: We reviewed all the registration studies of currently approved ICIs, CAR-T cells, and BiTEs to collect all the reported infections. For each drug, we have generated a report with the infections occurring in at least 10% of the patients enrolled. Results: The most frequently reported infections involving patients treated with ICIs involved the respiratory tract, including nasopharyngitis, upper respiratory tract infections, and pneumonia and the urinary tract. Those treated with CAR-T cells frequently reported the incidence of unspecified infections and infestations, bacterial infections, and viral infections. In patients treated with BiTEs, nasopharyngitis, pneumonia, and device-related infections were the most frequently reported conditions. Conclusions: A wide range of infections are reported in registration studies and clinical trials of ICIs, CAR-T cells, and BiTEs.(c) 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/